Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

337
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
337
Psychoneuroimmunology: Cardiovascular Disease01:27

Psychoneuroimmunology: Cardiovascular Disease

25
Psychoneuroimmunology (PNI) is a multidisciplinary field that examines how psychological factors, particularly stress, interact with the immune system and impact physical health. Research in PNI has shown that chronic or traumatic stress can disrupt both the hypothalamic-pituitary-adrenal axis and the sympathetic nervous system. These disruptions contribute to serious health conditions, including cardiovascular diseases.
A key area of focus in PNI is the relationship between stress and coronary...
25
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

60
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
60
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

739
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
739
Assessment of the Cardiovascular System I: Subjective Data01:23

Assessment of the Cardiovascular System I: Subjective Data

280
A thorough health history and physical assessment are essential for identifying cardiovascular disease (CVD) symptoms and distinguishing them from other health issues.
Initial Enquiry
Ask the patient about their primary concern and thoroughly explore all reported symptoms.
Medical History
Investigate past illnesses affecting the cardiovascular system, such as angina, anemia, rheumatic fever, congenital heart disease, stroke, thrombophlebitis, dysrhythmias, varicosities
Inquire about symptoms...
280
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

103
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
103

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Country-specific differences in the association between obesity risk factors in two high-income countries: a cross-sectional analysis from the Prospective Urban Rural Epidemiology (PURE) study.

BMC public health·2026
Same author

Kidney function changes associated with trastuzumab use in women with breast cancer: a retrospective cohort study.

Breast cancer research and treatment·2026
Same author

Androgen deprivation therapy and kidney function in patients with prostate cancer: an analysis of the RADICAL-PC cohort.

International urology and nephrology·2026
Same author

Immune Checkpoint Inhibitor-Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement.

JAMA oncology·2025
Same author

Efficacy and cardiovascular safety of liposomal doxorubicin: a systematic review and meta-analysis of randomized trials.

Cardio-oncology (London, England)·2025
Same author

Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL).

Clinical lymphoma, myeloma & leukemia·2025
Same journal

The Heart-Brain Connection.

Cardiology clinics·2026
Same journal

Overcoming Psychological Barriers to Treatment Adherence: The Case of Antihypertensive Medication.

Cardiology clinics·2026
Same journal

Cardio-oncology Rehabilitation and Mental Health: Current Evidence and Future Perspectives.

Cardiology clinics·2026
Same journal

Cardiac Rehabilitation and Mental Health.

Cardiology clinics·2026
Same journal

Best-Practice Mental Health Interventions Following Acute Cardiovascular Events.

Cardiology clinics·2026
Same journal

Positive Psychology Interventions and Cardiovascular Health: Frequency and Duration to Sustain Cardiovascular Benefits.

Cardiology clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K

Cardiovascular Risk in Prostate Cancer.

Darryl P Leong1, Filipe Cirne2, Jehonathan H Pinthus3

  • 1Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada; Department of Medicine, McMaster University and Hamilton Health Sciences, Hamilton, Canada.

Cardiology Clinics
|November 17, 2024
PubMed
Summary
This summary is machine-generated.

Patients with prostate cancer frequently have cardiovascular disease, a leading cause of death. Treatment like androgen deprivation therapy (ADT) may increase cardiovascular risks, necessitating further research and guideline adherence.

Keywords:
Androgen deprivation therapyCardio-oncologyCardiovascular diseaseProstate cancerRisk factors

More Related Videos

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.5K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.4K

Related Experiment Videos

Last Updated: Jun 7, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

4.5K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

45.4K

Area of Science:

  • Oncology
  • Cardiology
  • Endocrinology

Background:

  • Cardiovascular disease (CVD) is highly prevalent in prostate cancer patients and a significant cause of mortality.
  • Existing cardiovascular risk factors in this population are often undertreated according to current guidelines.
  • Androgen deprivation therapy (ADT), a common prostate cancer treatment, is associated with metabolic changes that may increase CVD risk.

Purpose of the Study:

  • To evaluate the relationship between androgen deprivation therapy (ADT) and adverse cardiovascular events in prostate cancer patients.
  • To assess the potential incremental cardiovascular risks associated with androgen receptor signaling inhibitors and CYP17A1 inhibitors.
  • To examine the comparative cardiovascular risk between gonadotropin-releasing hormone antagonists and agonists.

Main Methods:

  • Review of existing literature and clinical data concerning prostate cancer treatments and cardiovascular outcomes.
  • Analysis of the impact of ADT on cardiovascular risk factors such as diabetes and hypertension.
  • Exploration of the cardiovascular safety profiles of different classes of hormonal therapies, including inhibitors.

Main Results:

  • ADT is linked to increased adiposity and risk of diabetes and hypertension, though its direct association with cardiovascular events needs further confirmation.
  • Androgen receptor signaling inhibitors and CYP17A1 inhibitors may add to the risks of hypertension and cardiovascular events in patients on ADT.
  • Preliminary evidence suggests potentially lower cardiovascular risk with gonadotropin-releasing hormone antagonists compared to agonists, requiring confirmation.

Conclusions:

  • Cardiovascular risk management is critical in prostate cancer patients, especially those undergoing ADT.
  • Specific hormonal therapies may influence cardiovascular event rates, necessitating careful patient selection and monitoring.
  • Further randomized clinical trials are required to confirm the comparative cardiovascular safety of different ADT agents.